Literature DB >> 2655967

The ESVEM trial. Electrophysiologic Study Versus Electrocardiographic Monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. The ESVEM Investigators.

.   

Abstract

ESVEM (Electrophysiologic Study Versus Electrocardiographic Monitoring) is an ongoing multicenter trial supported by the National Heart, Lung, and Blood Institute that began enrollment of patients on October 1, 1985. We describe here the methodology of the trial and data regarding enrollment of patients in the trial. The purpose of the trial is to determine whether electrophysiologic study or electrocardiographic Holter monitoring more accurately predicts antiarrhythmic drug efficacy in patients with aborted sudden death or sustained ventricular tachyarrhythmias. Consenting patients with inducible, sustained ventricular tachyarrhythmias and at least 480 premature ventricular contractions during 48 hours are randomized to undergo antiarrhythmic drug selection either by electrophysiologic study or by Holter monitoring. Up to six drugs (mexiletine, pirmenol, procainamide, propafenone, quinidine, and sotalol) are assessed in random order until one is predicted effective. An efficacy prediction is achieved in the electrophysiology limb if ventricular tachyarrhythmias are no longer inducible and in the Holter limb if ventricular ectopy is largely suppressed. Patients in whom a drug is predicted effective are followed while they are taking that drug to detect one of the three primary endpoints: arrhythmia recurrence, sudden death, or unmonitored syncope. In the first 37 months, 967 patients satisfied inclusion and exclusion criteria to undergo baseline studies. Two hundred eighty-six were eligible for and consented to randomization. In total, approximately 500 patients will be randomized and 285 subjects will be followed while receiving drugs that are predicted effective in this trial. Approximately 70 patients are expected to attain a primary end-point during a mean follow-up ot 3 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655967     DOI: 10.1161/01.cir.79.6.1354

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis.

Authors:  Kenji Yodogawa; Yoshihiko Seino; Toshihiko Ohara; Hideo Takayama; Takao Katoh; Kyoichi Mizuno
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-04       Impact factor: 1.468

2.  Intracoronary arterial occlusion: a novel technique potentially useful for ablation of cardiac arrhythmias.

Authors:  T Y Hsia; M Billingham; R J Sung
Journal:  J Interv Card Electrophysiol       Date:  1997-02       Impact factor: 1.900

Review 3.  When is drug therapy warranted to prevent sudden cardiac death?

Authors:  B N Singh
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 5.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

6.  Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.

Authors:  S Ogawa; H Mitamura; H Katoh
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

7.  [Holter monitoring and programmed ventricular stimulation].

Authors:  B D Gonska
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1997-12

8.  A modified approach for programmed electrical stimulation in mice: Inducibility of ventricular arrhythmias.

Authors:  Lukas Clasen; Christian Eickholt; Stephan Angendohr; Christiane Jungen; Dong-In Shin; Birgit Donner; Alexander Fürnkranz; Malte Kelm; Nikolaj Klöcker; Christian Meyer; Hisaki Makimoto
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

9.  Antiarrhythmic Drugs for Atrial Fibrillation: Selected Features of Ventricular Repolarization That Facilitate Proarrhythmic Torsades de Pointes and Favor Inpatient Initiation.

Authors:  James A Reiffel
Journal:  J Innov Card Rhythm Manag       Date:  2021-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.